Patient-reported reactogenicity and safety of COVID-19 vaccinations vs. comparator vaccinations: a comparative observational cohort studyarticle Published on 2023-09-192024-09-02 Journal: BMC Medicine [Category] 대상포진, [키워드] Adverse drug reaction COVID-19 Medical consultation observational study reactogenicity SARS-CoV-2 survey Vaccine [DOI] 10.1186/s12916-023-03064-6 PMC 바로가기 [Article Type] article
Immunogenicity and Safety of Vaccines against Coronavirus Disease in Actively Treated Patients with Solid Tumors: A Prospective Cohort StudyGeneral Published on 2023-07-092024-09-05 Journal: Cancer research and treatment [Category] update2024, [키워드] Chemotherapy COVID-19 vaccine immunogenicity reactogenicity solid cancer [DOI] 10.4143/crt.2022.1541 PMC 바로가기 [Article Type] General
Reactogenicity and safety of COVID-19 primary immunisation and booster vaccination regimens: a comparative observational cohort studyarticle Published on 2023-06-202024-09-02 Journal: BMC Medicine [Category] 대상포진, [키워드] Adverse drug reaction COVID-19 Medical consultation observational study reactogenicity survey Vaccines [DOI] 10.1186/s12916-023-02924-5 PMC 바로가기 [Article Type] article
Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12–17 year-old adolescentsCoronavirus Published on 2023-05-252024-09-05 Journal: Human vaccines & immunotherapeutics [Category] update2024, [키워드] adolescents COVID-19 immunogenicity reactogenicity SCB-2019 Vaccine [DOI] 10.1080/21645515.2023.2206359 PMC 바로가기 [Article Type] Coronavirus
Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort studyArticle Published on 2023-03-012023-07-11 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), [키워드] BNT162b2 ChAdOx1-S heterologous prime-boost immunogenicity reactogenicity [DOI] 10.1016/j.ijid.2022.12.034 PMC 바로가기
Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study건강한 성인에서 이종 및 동종 불활성화 및 아데노바이러스 매개 COVID-19 백신 요법의 안전성 및 면역원성: 전향적 코호트 연구Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] Adults adverse event adverse events Antibody Response AstraZeneca ChAdOx1 ChAdOx1-S circulating variants combinations CoronaVac country COVID-19 COVID-19 vaccine COVID-19 vaccines dose doses Efficacy Evidence evidence of followed by group groups healthy Heterologous heterologous adenoviral vector heterologous vaccine homologous IgA response immune response immune responses immunized immunogenicity inactivated Inactivated vaccine interferon gamma Mild neutralizing activities Neutralizing activity prospective cohort study reactogenicity Receptor-binding domain referred to regimen Safety Serious Adverse Event Serious Adverse Events supply shortage vaccination Vaccine variants variants of concern Viral viral vectored wild-type [DOI] 10.1080/21645515.2022.2029111 PMC 바로가기 [Article Type] Article
Vaccine Side Effects in Health Care Workers after Vaccination against SARS-CoV-2: Data from TüSeRe:exact StudyArticle Published on 2022-12-252023-07-11 Journal: Viruses [Category] COVID19(2023년), [키워드] adverse event COVID-19 reactogenicity Vaccine [DOI] 10.3390/v15010065 PMC 바로가기
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trialArticle Published on 2022-12-012022-10-06 Journal: The Lancet Regional Health - Western Pacific [Category] 진단, [키워드] acute respiratory syndrome Administered Adults adverse event AEs age Analysis assessment assigned BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine China Chinese clinical trial Complete Completed conducted coronavirus COVID-19 development dose double-blind Efficacy and safety enrolled Follow-up geometric mean titer GMT GMTs Han Chinese healthy immune response immunogenicity immunogenicity endpoint Inc independent individual injection intramuscular Intramuscular injection investigators Laboratory parameters management messenger Messenger RNA Mild moderate mRNA vaccine Neutralising Antibodies neutralising antibody of BNT162b2 participant Participants pharmaceutical Placebo placebo-controlled trial randomisation randomised Randomly reactogenicity receive recipients recruited reduced remained reported resolved Result robust Safety SARS-CoV-2 SARS-CoV-2 variant SCR second dose sera serious AE seroconversion rate severity Shanghai Sponsor statisticians stratified T-cell Response the placebo group Tolerability Treatment Trial utilised vaccination vaccine administration were blinded [DOI] 10.1016/j.lanwpc.2022.100586 PMC 바로가기 [Article Type] Article
Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccinesCoronaVac 및 ChAdox1 nCov-19(AZD1222) 백신으로 이종 프라임-부스트 백신 접종 후 면역원성 및 반응성Article Published on 2022-11-302022-09-12 Journal: Human vaccines & immunotherapeutics [Category] MERS, 진단, [키워드] 95% CI 95% confidence interval Administered age age and sex antibody assigned AZD1222 binding domain booster dose Care ChAdOx1 nCoV-19 Cohort cohorts Combination Concentration control group CoronaVac COVID-19 COVID-19 pandemic effective elicited enrolled finding geometric mean ratio GMR Health Heterologous heterologous prime-boost homologous immune response immunogenicity indicated mass participant primary endpoint prime-boost interval RBD reactogenicity robust Safe the median vaccination Vaccine vaccine administration vaccine combination. while [DOI] 10.1080/21645515.2022.2052525 PMC 바로가기 [Article Type] Article
Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine in children and adolescents 6 months through 17 years of age in IndiaClinical Trial Published on 2022-11-302023-06-24 Journal: Human vaccines & immunotherapeutics [Category] 신종인플루엔자, [키워드] adolescents children hemagglutination immunogenicity Influenza quadrivalent influenza vaccine reactogenicity [DOI] 10.1080/21645515.2022.2104527 PMC 바로가기 [Article Type] Clinical Trial